Perifosine
Chemical compound
From Wikipedia, the free encyclopedia
Perifosine (also KRX-0401) is a former drug candidate that was under development for a variety of cancer indications. It is an alkyl-phospholipid[1] structurally related to miltefosine. Perifosine interrupts the PI3K/AKT/mTOR pathway by acting as an allosteric AKT inhibitor targeting the pleckstrin homology domain of AKT.[2] It was being developed by Keryx Biopharmaceuticals who had licensed it from Æterna Zentaris Inc.[3]
| |
 | |
| Names | |
|---|---|
| IUPAC name
1,1-Dimethylpiperidinium-4-yl octadecyl phosphate | |
| Other names
D 21266; KRX 0401 | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.217.789 |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C25H52NO4P | |
| Molar mass | 461.668 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
In 2010, perifosine received orphan drug status in the U.S. for the treatment of multiple myeloma and neuroblastoma, and for multiple myeloma in the EU.[4] However, both were later withdrawn.[5][6]
In 2011 it was in a phase III trial for colorectal cancer,[7] and another for multiple myeloma.[4][8] On April 2, 2012, it was announced that perifosine failed its phase III clinical trial for treatment of colon cancer.[9] Detailed results were released in June 2012.[10] On March 11, 2013, Aeterna Zentaris announced the discontinuing of Phase 3 clinical trial of perifosine for the treatment of relapsed and refractory multiple myeloma.[11]